Discussing the appropriate use and future of Pluvicto Radionuclide Therapy amidst the developing treatment landscape for genitourinary cancers.

Executed on:Feb 2, 2024 8:00 AM EDT

Call Duration:30 minutes

Expert Profile

ExpertBlinded Expert

Institution: University of Minnesota (formerly Hopkins)

Associate Director for Translational Research at the Masonic Cancer Center & Director of Genitourinary Oncology Hematology, Oncology, and Transplantation) at the University of Minnesota Medical School.
Clinical interest is the management of prostate cancer and other genitourinary malignancies. 
Research focuses on developing novel androgen-directed therapies, genetically-targeted therapies, and immunotherapies for men with recurrent or advanced prostate cancer, and using germline and cancer genomics to inform precision oncology approaches. 

Interview Goal

On this call we will be discussing radiopharmaceuticals and the future of Pluvicto Radionuclide Therapy amidst the developing treatment landscape for genitourinary cancers, as well as touching on Bristol Myers Squibb's acquisition of Rayze Bio.

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.